JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dalm, V. A.S.H.
Right arrow Articles by van Hagen, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dalm, V. A.S.H.
Right arrow Articles by van Hagen, M. P.

Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy?

Virgil A.S.H. Dalm, PhD1, Leo J. Hofland, PhD1, Cornelia M. Mooy, MD, PhD2, Marlijn A. Waaijers1, Peter M. van Koetsveld1, Anton W. Langerak, PhD3, Frank T.J. Staal, PhD3, Aart-Jan van der Lely, MD, PhD1, Steven W.J. Lamberts, MD, PhD1 and Martin P. van Hagen, MD, PhD1,3

1 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
2 Department of Ophthalmic Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
3 Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands



View larger version (14K):

[in a new window]
  		FIGURE 1. Autoradiography experiments on lymphomas. (Top) Binding of [125I-Tyr3]octreotide, represented by black spots, to rat brain (A), GH-producing tumor (B), both used as positive controls, and example of 1 lymphoma studied (C), lymphoma no. 6. (Bottom) Binding of [125I-Tyr3]octreotide is displaced by excess unlabeled octreotide.

 


View larger version (14K):

[in a new window]
  		FIGURE 2. Membrane binding studies. Scatchard analysis of [125I-Tyr3]octreotide binding on human B and myeloid cell lines: {diamond}, B-CLL (dissociation constant [Kd] = 0.8 nmol/L, n = 50 fmol/mg); {blacksquare}, APD cell line (Kd = 0.7 nmol/L, n = 40 fmol/mg); •, TMM cell line (Kd = 0.4 nmol/L, n = 100 fmol/mg); {blacktriangledown}, JY cell line (Kd = 0.4 nmol/L, n = 195 fmol/mg); {triangleup}, CC2B cell line (Kd = 0.8 nmol/L, n = 460 fmol/mg).

 


View larger version (15K):

[in a new window]
  		FIGURE 3. Internalization experiment using CC2B, JY, TMM, APD, and B-CLL cells. Cells were incubated either with [125I-Tyr3]octreotide alone or with [125I-Tyr3]octreotide and excess of unlabeled octreotide (1 µmol/L) for 30, 60, and 120 min, respectively. At each time point, internalization was measured. Results are presented as amount of radiolabeled compound internalized by cell in fmol/106 cells and as degree of internalization for 106 cells as percentage of administered dose.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.